Skip to main content

Table 1 French guidelines for cART initiation from 2000 to 2010

From: The effect of adherence to guidelines for initial antiretroviral therapy on 1-year outcomes: a French cohort study

a "when-to-start" guidelines
  2000 2002 2004 2006 2008 2010
CDC B-C Rec. Rec. Rec. Rec. Rec. Rec.
CD4 < 200/mm3 Rec. Rec. Rec. Rec. Rec. Rec.
CD4 < 15% Rec. Rec. Rec. Rec. Rec. Rec.
CD4 200-349/mm3 Rec. Opt. (1) Rec. Rec. Rec. Rec.
CD4 350-500/mm3   NR Opt. (1) Opt. (1) Opt. (2) Rec.
CD4 > 500/mm3   NR NR NR NR Opt. (3)
b "what-to-start" guidelines
  2000 2002 2004 2006 2008 2010
NRTIs Backbone       
ZDV + ddI Pref. Pref. Alt. Pref. NR NR
ZDV +3TC Pref. Pref. Pref. Pref. Alt. Alt.
d4T + ddI Pref. NR NR NR NR NR
d4T +3TC Pref. Pref. Alt. NR NR NR
ZDV + FTC   Alt. Pref. Pref. Alt. Alt.
TDF +3TC   Alt. Pref. Pref. Pref. Alt.
TDF + FTC   Alt. Pref. Pref. Pref. Pref.
ddI +3TC   Alt. Pref. Pref. Pref. NR
ddI + FTC   Alt. Pref. Pref. Pref. NR
ABC +3TC   Alt. Pref. Pref. Pref. Pref.
ABC + FTC   Alt. Pref. Pref. Pref. Alt.
ddI + TDF   Alt. Alt. NR NR NR
3 NRTIs combinations       
ABC +3TC + ddI   Alt. NR NR NR NR
ABC +3TC + d4T   Alt. NR NR NR NR
ZDV +3TC + ddI   Alt. NR NR NR NR
ABC +3TC + TDF   Alt. NR NR NR NR
TDF + ddI +3TC   Alt. NR NR NR NR
ZDV +3TC + ABC Pref. Pref. Alt. (1) Alt. (1) NR NR
Other 3 NRTI combinations   Alt. NR NR NR NR
Unboosted PIs       
RTV Pref. NR NR NR NR NR
IDV Pref. NR NR NR NR NR
NFV Pref. Pref. Alt. NR   
Boosted PIs       
APVr Alt. Alt.     
SQVr Pref. Pref. Pref. Pref. Alt. Alt.
IDVr Alt. Pref. Pref. Alt. Alt. Alt.
LPVr Alt. Pref. Pref. Pref. Pref. Pref.
fAPVr    Pref. Pref. Pref. Alt.
ATVr     Alt. Pref. Pref.
DRVr     NR Alt. Pref.
NNRTIs       
EFV Pref. Pref. Pref. Pref. Pref. Pref.
NVP Pref. Pref. Pref. Alt. Alt. Alt.
Integrase Inhibitor       
RAL       Alt.
Antiretroviral combinations       
NNRTI + PI (boosted or not)     NR NR NR
2 NRTIs +1 NNRTI Pref. Pref. Pref. Pref. Pref. Pref.
2 NRTIs +1 PI Pref. Pref. Alt. NR NR NR
2 NRTIs +1 boosted PI Pref. Pref. Pref. Pref. Pref. Pref.
Boosted PI monotherapy     NR NR NR
  1. Abbreviations: Rec ART recommended, Opt ART optional, NR ART Not recommended; (1), if HIV-RNA >105 log copies/ml; (2), if HIV-RNA >105 log copies/ml >50 years, HBV/HCV coinfection or high cardiovascular risk; (3), if HIV-RNA >105 log copies/ml, >50 years, HBV/HCV coinfection, high cardiovascular risk or treatment as prevention.
  2. Abbreviations: ZDV zidovudine, ddI didanosine, 3TC lamivudine, d4T stavudine, FTC emtricitabine, TDF tenofovir, ABC abacavir, NRTI nucleoside/nucleotide reverse transcriptase inhibitors, PI protease inhibitor, RTV ritonavir, IDV indinavir, NFV nelfinavir, APVr boosted amprenavir, SQVr boosted saquinavir, IDVr boosted indinavir, LPVr boosted lopinavir, fAPVr boosted fosamprenavir, ATVr boosted atazanavir, DRVr boosted darunavir, NNRTI non-nucleoside reverse transcriptase inhibitors, EFV efavirenz, NVP nevirapine, RAL raltegravir, Pref preferred, Alt alternative, NR Not recommended; (1), if HIV-RNA <105 log copies/ml.